Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

56.75 -1.50 (-2.58%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	5,097,828
Open	57.91
Bid (Size)	56.64 (100)
Ask (Size)	56.88 (500)
Prev. Close	58.25
Today's Range	56.11 - 57.91
52wk Range	40.03 - 86.74
Shares Outstanding	141,797,854
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗

Today 12:25 EDT

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

Via MarketBeat

IONS Investor Alert: Levi & Korsinsky Notifies Investors of an Investigation Into Ionis Pharmaceuticals (IONS)

Today 10:00 EDT

From Levi & Korsinsky, LLP

Via Business Wire

Performance

YTD	-28.8%	-28.8%
1 Month	-22.6%	-22.6%
3 Month	-24.3%	-24.3%
6 Month	-30.5%	-30.5%
1 Year	+33.4%	+33.4%

More News

Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome

Today 7:00 EDT

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharmaceuticals (NASDAQ:IONS) Shares Surge After Crushing Q1 Estimates and Raising Full-Year Guidance ↗

April 29, 2026

Via Chartmill

Which stocks are experiencing notable movement on Thursday? ↗

July 09, 2026

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

July 09, 2026

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

July 09, 2026

Via Chartmill

Discover the top movers in Thursday's pre-market session. ↗

July 09, 2026

Via Chartmill

Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy

July 09, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome

July 06, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.

June 25, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)

June 24, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗

June 19, 2026

Via InvestorPlace

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

June 08, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

June 04, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗

May 31, 2026

Via The Motley Fool

Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

May 28, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts ↗

May 25, 2026

Via MarketBeat

Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference ↗

May 18, 2026

Via MarketBeat

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease

May 14, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to host 2026 virtual Annual Meeting of Stockholders

May 04, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis to present at upcoming investor conferences

May 01, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis (IONS) Q1 2026 Earnings Call Transcript ↗

April 29, 2026

Via The Motley Fool

Ionis reports first quarter 2026 financial results and highlights progress on key programs

April 29, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

April 28, 2026

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?

Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market

What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?

The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 56.75

When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 07/13/26 04:00 PM ET

What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 8.05B

How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?

Ionis Pharmaceuticals, Inc. - Common Stock has 8B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.